Yohimbine increases the release of NE in the PVN by inhibiting the signaling pathway of α2-AR, suggesting that the functional change of the presynaptic membrane α2 receptor has a connection with the targets for the treatment of depression. Here, ADORA2A is linked to depressive symptom measurement.